Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 3, Pages 2645
Publisher
MDPI AG
Online
2023-01-31
DOI
10.3390/ijms24032645
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
- (2022) Natalie S. Callander et al. Journal of the National Comprehensive Cancer Network
- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Modulation of cellular processes by histone and non-histone protein acetylation
- (2022) Maria Shvedunova et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
- (2022) Fredrik H Schjesvold et al. Lancet Haematology
- Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams
- (2022) Darren Pan et al. Frontiers in Oncology
- Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
- (2022) Dusan Ruzic et al. Pharmaceutics
- Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies
- (2022) Rand Shahin et al. Future Science OA
- Daratumumab in first-line is cost-effective in transplant-eligible newly diagnosed myeloma patients.
- (2022) Chihiro Yamamoto et al. BLOOD
- Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
- (2022) Lugui Qiu et al. BMC Medicine
- Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
- (2022) Sikander Ailawadhi et al. HEMATOLOGICAL ONCOLOGY
- The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
- (2022) Timothée Olivier et al. Translational Oncology
- Cost-effectiveness: maximizing impact by meticulous data
- (2022) Hedwig M. Blommestein et al. BLOOD
- Solving the nuclear pore puzzle
- (2022) Thomas U. Schwartz SCIENCE
- Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
- (2022) Ricardo D. Parrondo et al. Cancers
- Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
- (2022) Fredrik H Schjesvold et al. Translational Oncology
- Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
- (2022) Sagar Lonial et al. Lancet Haematology
- CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
- (2022) Joanna Barankiewicz et al. Cancers
- Preliminary Results from the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma
- (2022) Chunyan Sun et al. BLOOD
- Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study
- (2022) Hang Quach et al. BLOOD
- Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma
- (2022) Wenjiao Tang et al. BLOOD
- Melflufen: A Next-Generation Nitrogen Mustard
- (2021) Sarah A. Holstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
- (2021) Ichiro Hanamura Cancers
- Combinations of histone post-translational modifications
- (2021) Bethany C. Taylor et al. BIOCHEMICAL JOURNAL
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
- (2021) Max Jan et al. Nature Reviews Clinical Oncology
- Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
- (2021) Holger W. Auner et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
- (2021) Logan Good et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
- (2021) Maria V. Mateos et al. Journal of Hematology & Oncology
- Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma
- (2021) Yu-bo Zhou et al. ACTA PHARMACOLOGICA SINICA
- Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
- (2021) Gabriel Tremblay et al. BMC CANCER
- Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
- (2021) Ajai Chari et al. Clinical Lymphoma Myeloma & Leukemia
- Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy
- (2021) Swati Krishna et al. COMPUTERS IN BIOLOGY AND MEDICINE
- Bromodomains: A novel target for the anticancer therapy
- (2021) Shivani Gokani et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- BH3 Mimetics in Hematologic Malignancies
- (2021) Pavel Klener et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
- (2021) Nizar J. Bahlis et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
- (2021) Cristina Gasparetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).
- (2021) Darrell White et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-β signaling pathway.
- (2021) Ehsan Malek et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure, Maintenance, and Regulation of Nuclear Pore Complexes: The Gatekeepers of the Eukaryotic Genome
- (2021) Marcela Raices et al. Cold Spring Harbor Perspectives in Biology
- Deubiquitinases in hematological malignancies
- (2021) Hu Lei et al. Biomarker Research
- Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
- (2021) Luciano J Costa et al. Blood Advances
- Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis
- (2021) Azka Latif et al. Cardiovascular and Hematological Disorders - Drug Targets
- A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma
- (2021) Robert Frank Cornell et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients
- (2021) Weiqin Yao et al. BLOOD
- Trial in Progress: Phase 1b/2 Open-Label Study of Lisaftoclax (APG-2575) Monotherapy or in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM)
- (2021) Chengcheng Fu et al. BLOOD
- Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
- (2021) Jonathan L. Kaufman et al. BLOOD
- Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study
- (2021) Paula Rodríguez-Otero et al. BLOOD
- Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- (2021) Shaji Kumar et al. BLOOD
- P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma
- (2021) Sagar Lonial et al. Clinical Lymphoma Myeloma & Leukemia
- Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials
- (2021) Avash Das et al. HEMATOLOGICAL ONCOLOGY
- Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review
- (2021) Hassaan Imtiaz et al. OncoTargets and Therapy
- Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
- (2021) Darren Pan et al. Cancer Medicine
- Therapeutic targeting of “undruggable” MYC
- (2021) Victor Llombart et al. EBioMedicine
- Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
- (2020) Ajai Chari et al. HEMATOLOGICAL ONCOLOGY
- Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
- (2020) Eric K. Rowinsky et al. INVESTIGATIONAL NEW DRUGS
- Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
- (2020) Joshua D. Hansen et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Frequency of Ras Mutations in Cancer
- (2020) Ian A. Prior et al. CANCER RESEARCH
- Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
- (2020) Cristina Gasparetto et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- (2020) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
- (2020) Cristina Gasparetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
- (2020) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.
- (2020) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
- (2020) David S. Siegel et al. LEUKEMIA
- Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
- (2020) Giorgio Milazzo et al. Genes
- Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group
- (2020) Enrique M. Ocio et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Trial Evaluating Vorinostat plus Bortezomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
- (2020) Jonathan L. Kaufman et al. Clinical Lymphoma Myeloma & Leukemia
- The roles of histone variants in fine-tuning chromatin organization and function
- (2020) Sara Martire et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Molecular mechanisms of thalidomide and its derivatives
- (2020) Takumi ITO et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma
- (2020) Joel G Turner et al. CANCER RESEARCH
- Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents
- (2020) Xing Lu et al. CURRENT MOLECULAR MEDICINE
- Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
- (2020) Meletios Dimopoulos et al. LEUKEMIA
- Epigenetic Aberrations in Multiple Myeloma
- (2020) Cinzia Caprio et al. Cancers
- Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
- (2020) Jonathan L. Kaufman et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial
- (2020) Sarah Brown et al. Clinical Lymphoma Myeloma & Leukemia
- Small-Molecule Approaches to Targeted Protein Degradation
- (2020) Tyler B. Faust et al. Annual Review of Cancer Biology-Series
- Ixazomib – the first oral proteasome inhibitor
- (2019) Jingmei Xie et al. LEUKEMIA & LYMPHOMA
- The multiple mechanisms that regulate p53 activity and cell fate
- (2019) Antonina Hafner et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Cancer statistics for African Americans, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
- (2019) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
- (2019) Kerry A. Rogers et al. LEUKEMIA
- TAS4464, a highly potent and selective inhibitor of NEDD8 activating enzyme, suppresses neddylation and shows antitumor activity in diverse cancer models
- (2019) Chihoko Yoshimura et al. MOLECULAR CANCER THERAPEUTICS
- Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies
- (2019) Hélène M. Faessel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
- (2019) W. Larry Gluck et al. INVESTIGATIONAL NEW DRUGS
- T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
- (2019) Simo Xia et al. Cellular & Molecular Immunology
- Selinexor: First Global Approval
- (2019) Yahiya Y. Syed DRUGS
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer drug discovery by targeting cullin neddylation
- (2019) Qing Yu et al. Acta Pharmaceutica Sinica B
- Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
- (2019) Hong-Hui Huang et al. BLOOD
- Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients
- (2019) Jingjing Shang et al. BLOOD
- Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
- (2019) Sikander Ailawadhi et al. BLOOD
- A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma
- (2019) Andrew Spencer et al. Clinical Lymphoma Myeloma & Leukemia
- A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
- (2019) Hans C. Lee et al. Blood Cancer Journal
- Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
- (2019) Timothy M. Schmidt et al. Blood Cancer Journal
- Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
- (2019) Meera Mohan et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase 2 Study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
- (2019) Roman Hajek et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Filanesib for the treatment of multiple myeloma
- (2019) Esperanza Macarena Algarín et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor
- (2019) Teresa Ho et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
- (2018) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases
- (2018) Jie Ying et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
- (2018) Johannes M. Waldschmidt et al. HAEMATOLOGICA
- Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
- (2018) Johannes M. Waldschmidt et al. HAEMATOLOGICA
- Ibrutinib and Aspergillus: a Btk-targeted risk
- (2018) Jennifer A. Woyach BLOOD
- A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
- (2017) Mary E. Matyskiela et al. JOURNAL OF MEDICINAL CHEMISTRY
- From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
- (2017) Avi Ashkenazi et al. NATURE REVIEWS DRUG DISCOVERY
- Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target
- (2017) Ping Xie et al. Cell Death & Disease
- Current Review on High-Risk Multiple Myeloma
- (2017) Henry S. H. Chan et al. Current Hematologic Malignancy Reports
- Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
- (2017) Fraser Aird et al. eLife
- Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
- (2017) J Xu et al. Oncogenesis
- Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
- (2017) Brian J. North et al. PLoS One
- Identification of a p53-based portable degron based on the MDM2-p53 binding region
- (2016) Adam T. Melvin et al. ANALYST
- Bromodomains: Structure, function and pharmacology of inhibition
- (2016) Elena Ferri et al. BIOCHEMICAL PHARMACOLOGY
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- (2016) N. Weinhold et al. BLOOD
- A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells
- (2016) Arghya Ray et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma
- (2016) Ajai Chari et al. CANCER
- VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
- (2016) David S. Siegel et al. Clinical Lymphoma Myeloma & Leukemia
- Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation
- (2016) Ulrich J.M. Mey et al. HEMATOLOGICAL ONCOLOGY
- Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
- (2016) Joel G. Turner et al. Journal of Hematology & Oncology
- Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
- (2016) Brian K. Albrecht et al. JOURNAL OF MEDICINAL CHEMISTRY
- Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules
- (2016) Jeremy L. Yap et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
- (2016) Andrew J Yee et al. LANCET ONCOLOGY
- Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma
- (2016) S. Li et al. MOLECULAR CANCER THERAPEUTICS
- The Transactivation Domains of the p53 Protein
- (2016) Nitin Raj et al. Cold Spring Harbor Perspectives in Medicine
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
- (2016) Xin Wang et al. Scientific Reports
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
- (2015) P. G. Richardson et al. BLOOD
- CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
- (2015) P. R. Hagner et al. BLOOD
- Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
- (2015) David H. Vesole et al. BRITISH JOURNAL OF HAEMATOLOGY
- Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide
- (2015) Deepika S. Das et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma
- (2015) Douglas W. Sborov et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
- (2015) J. J. Shah et al. CLINICAL CANCER RESEARCH
- The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma
- (2015) Paul G Richardson et al. Future Oncology
- Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
- (2015) A. Gunther et al. HAEMATOLOGICA
- Targeting the TGFβ pathway for cancer therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- Targeting BET bromodomains for cancer treatment
- (2015) Marie Jung et al. Epigenomics
- Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
- (2015) A. Gunther et al. HAEMATOLOGICA
- Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma
- (2015) Maria Todaro et al. CANCER RESEARCH
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma
- (2014) J.P. Sharman et al. Clinical Lymphoma Myeloma & Leukemia
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer
- (2014) Lihui Li et al. JNCI-Journal of the National Cancer Institute
- Lenalidomide induces degradation of IKZF1 and IKZF3
- (2014) Jan Krönke et al. OncoImmunology
- Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
- (2013) Mathew P. Martin et al. ACS Chemical Biology
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- (2013) J Schmidt et al. LEUKEMIA
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- Bruton's tyrosine kinase: potential target in human multiple myeloma
- (2013) Ying Liu et al. LEUKEMIA & LYMPHOMA
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
- (2012) Dharminder Chauhan et al. CANCER CELL
- The bromodomain interaction module
- (2012) Panagis Filippakopoulos et al. FEBS LETTERS
- Tyrosine Kinase Btk Is Required for NK Cell Activation
- (2012) Yan Bao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
- (2012) D. W. McMillin et al. MOLECULAR CANCER THERAPEUTICS
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
- (2011) W-J Chng et al. LEUKEMIA
- Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
- (2009) C. Choudhary et al. SCIENCE
- HDAC expression and clinical prognosis in human malignancies
- (2008) Wilko Weichert CANCER LETTERS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now